From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.